search
Back to results

Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting

Primary Purpose

Influenza

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
High Dose Inactivated Influenza Vaccine
Standard Dose Inactivated Influenza Vaccine
Sponsored by
University of Pittsburgh
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Influenza focused on measuring Influenza in Long Term Care Setting, High dose Inactivated influenza vaccine, Standard dose inactivated influenza vaccine

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Residents of one of the participating LTC sites
  • 65 years or older at the time of consent
  • require assistance in two or more Instrumental Activities of Daily Living and/or one or more Activities of Daily Living as identified by facility staff

Exclusion Criteria:

  • Age less than 65 years
  • Life expectancy less than 6 months
  • History of allergic reaction to influenza vaccine, its components, or eggs
  • History of severe allergic reaction to latex
  • History of Guillian-Barre Syndrome
  • Actively undergoing chemotherapy
  • Actively undergoing radiation therapy
  • Use of prednisone (or other steroid) at prednisone-equivalent dosages of 10mg or higher within the past 14 days
  • Serious current immunosuppression or immunosuppression expected in the next 6 weeks
  • Any condition that, in the opinion of the investigator,might interfere with the evaluation of study objectives

Sites / Locations

  • University of Pittsburgh, Division of Geriatric Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

High Dose Inactivated Influenza Vaccine

Standard Dose Inactivated Influenza Vaccine

Arm Description

For HDIV,0.5 ml of high dose inactivated influenza vaccine consisting of a total of 180mcg (60 mcg each strain) of influenza virus hemagglutinin

For SDIV, 0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg of each strain) of influenza virus hemagglutinin

Outcomes

Primary Outcome Measures

Non-inferiority of High-dose Inactivated Influenza Vaccine(HDIV) Versus Standard Dose Inactivated Influenza Vaccine(SDIV) Among Residents of Long Term Care(LTC) Settings
The primary objective of this study is to determine the noninferiority of high- dose inactivated influenza vaccine (HDIV) versus standard dose inactivated influenza vaccine(SDIV)among residents of long term care(LTC)settings.Non-inferiority will be determined by comparing baseline and one month post vaccination HAI and MN titers using non-inferiority analysis.
Non-inferiority of High-dose Inactivated Influenza Vaccine(HDIV) Versus Standard Dose Inactivated Influenza Vaccine(SDIV) Among Residents of Long Term Care(LTC) Settings
The primary objective of this study is to determine the noninferiority of high- dose inactivated influenza vaccine (HDIV) versus standard dose inactivated influenza vaccine(SDIV)among residents of long term care(LTC)settings.Non-inferiority will be determined by comparing baseline and one month post vaccination HAI and MN titers using non-inferiority analysis.

Secondary Outcome Measures

Non-inferiority and Immunoprotection Persistence at 6 Months
Compare the immunogenicity via HAI and MN titers for HDIV and SDIV at 6 months in frail LTC residents

Full Information

First Posted
July 27, 2012
Last Updated
June 13, 2017
Sponsor
University of Pittsburgh
Collaborators
Sanofi Pasteur, a Sanofi Company
search

1. Study Identification

Unique Protocol Identification Number
NCT01654224
Brief Title
Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting
Official Title
Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting
Study Type
Interventional

2. Study Status

Record Verification Date
June 2017
Overall Recruitment Status
Completed
Study Start Date
November 2011 (undefined)
Primary Completion Date
June 2014 (Actual)
Study Completion Date
June 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Pittsburgh
Collaborators
Sanofi Pasteur, a Sanofi Company

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the study is to compare the performance of two currently available influenza (flu) vaccines. This study will try and determine if the high dose flu vaccine provides protection that is the same or better than that of regular dose flu vaccine. Both the regular dose and the high dose flu vaccines are approved by the FDA for use in older adults.
Detailed Description
Influenza and pneumonia are the fifth leading cause of death in the United States, the leading cause of vaccine preventable death, and the leading cause of infection related deaths among nursing home residents(Nace, Drinka et al.2010). Each year, an estimated 36,000 individuals die from seasonal influenza and over 90% of these deaths occur among older adults, primarily the frail older adults residing in LTC settings(Fiore,Uyeki et al. 2010).Vaccination is the most effective means of preventing influenza (Nichol and Treanor 2006). Despite increasing success in immunizing LTC residents though, outbreaks continue to occur annually with case fatality rates ranging between 5-55% (Nace 2008). Older adults have a reduced response to influenza vaccination, in part due to age related immunosenescence (Keitel, Atmar et al. 1121; Skowronski, Tweed et al. 2008). It is widely recognized that more effective vaccine options are needed for frail older adults. One option is to increase the hemagglutinin (HA) dose in influenza vaccines in an effort to increase antibodies to hemagglutinin. To date, no studies have evaluated the effectiveness of the HDIV among LTC residents.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Influenza
Keywords
Influenza in Long Term Care Setting, High dose Inactivated influenza vaccine, Standard dose inactivated influenza vaccine

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
205 (Actual)

8. Arms, Groups, and Interventions

Arm Title
High Dose Inactivated Influenza Vaccine
Arm Type
Active Comparator
Arm Description
For HDIV,0.5 ml of high dose inactivated influenza vaccine consisting of a total of 180mcg (60 mcg each strain) of influenza virus hemagglutinin
Arm Title
Standard Dose Inactivated Influenza Vaccine
Arm Type
Active Comparator
Arm Description
For SDIV, 0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg of each strain) of influenza virus hemagglutinin
Intervention Type
Biological
Intervention Name(s)
High Dose Inactivated Influenza Vaccine
Intervention Description
0.5 ml HDIV consisting of 180 mcg (60 mcg each strain) of influenza virus hemagglutinin
Intervention Type
Biological
Intervention Name(s)
Standard Dose Inactivated Influenza Vaccine
Intervention Description
0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg each strain) of influenza virus hemagglutinin
Primary Outcome Measure Information:
Title
Non-inferiority of High-dose Inactivated Influenza Vaccine(HDIV) Versus Standard Dose Inactivated Influenza Vaccine(SDIV) Among Residents of Long Term Care(LTC) Settings
Description
The primary objective of this study is to determine the noninferiority of high- dose inactivated influenza vaccine (HDIV) versus standard dose inactivated influenza vaccine(SDIV)among residents of long term care(LTC)settings.Non-inferiority will be determined by comparing baseline and one month post vaccination HAI and MN titers using non-inferiority analysis.
Time Frame
30 days
Title
Non-inferiority of High-dose Inactivated Influenza Vaccine(HDIV) Versus Standard Dose Inactivated Influenza Vaccine(SDIV) Among Residents of Long Term Care(LTC) Settings
Description
The primary objective of this study is to determine the noninferiority of high- dose inactivated influenza vaccine (HDIV) versus standard dose inactivated influenza vaccine(SDIV)among residents of long term care(LTC)settings.Non-inferiority will be determined by comparing baseline and one month post vaccination HAI and MN titers using non-inferiority analysis.
Time Frame
Day 0
Secondary Outcome Measure Information:
Title
Non-inferiority and Immunoprotection Persistence at 6 Months
Description
Compare the immunogenicity via HAI and MN titers for HDIV and SDIV at 6 months in frail LTC residents
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Residents of one of the participating LTC sites 65 years or older at the time of consent require assistance in two or more Instrumental Activities of Daily Living and/or one or more Activities of Daily Living as identified by facility staff Exclusion Criteria: Age less than 65 years Life expectancy less than 6 months History of allergic reaction to influenza vaccine, its components, or eggs History of severe allergic reaction to latex History of Guillian-Barre Syndrome Actively undergoing chemotherapy Actively undergoing radiation therapy Use of prednisone (or other steroid) at prednisone-equivalent dosages of 10mg or higher within the past 14 days Serious current immunosuppression or immunosuppression expected in the next 6 weeks Any condition that, in the opinion of the investigator,might interfere with the evaluation of study objectives
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David A. Nace, MD, MPH, CMD
Organizational Affiliation
University of Pittsburgh, Division of Geriatric Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Pittsburgh, Division of Geriatric Medicine
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
25525051
Citation
Nace DA, Lin CJ, Ross TM, Saracco S, Churilla RM, Zimmerman RK. Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities. J Infect Dis. 2015 Jun 15;211(12):1915-24. doi: 10.1093/infdis/jiu622. Epub 2014 Dec 17.
Results Reference
result

Learn more about this trial

Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting

We'll reach out to this number within 24 hrs